Evolus CEO sells over $200k in company stock - Investing.com

Q: Is Evolus a profitable stock?

Full-year revenue guidance was “narrowed” to $260m - $266m — an annual uplift of 29% - 32% — and stated it would be profitable on a non-GAAP basis in Q4 2024, and in full-year 2025, and finally, that it: Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November.

Q: Should you buy Evolus stock after Q3 earnings?

Unfortunately, although Evolus stock enjoyed a strong bull run between June and early November last year, with shares reaching a high of $17 per share, a market cap valuation of roughly just under $1bn, it then began to tumble in value after Evolus released a weak set of Q3 earnings. At first, the results and updates appear quite positive.

Q: Should I buy Evolus?

My “Buy” recommendation was based on several factors. Firstly, the company has settled litigation with AbbVie (ABBV), who market and sell Botox, the leading product in the field, which earned $2.7bn in aesthetics markets, and $3bn as a migraine therapy, in 2023. AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau.

Q: Is Evolus launching a second product?

Well, between 2020 and 2023 Evolus nearly quadrupled its revenues, and it is in the process of launching a second product that could be even more lucrative.

Q: Did Evolus steal trade secrets?

AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. However, the litigation was settled, with AbbVie granting Evolus a license to keep selling its product.

May 14, 2024 · Evolus (NASDAQ: EOLS), Inc. CEO David Moatazedi recently completed a stock sale transaction, disposing of a total of 16,051 shares of the company's common stock, resulting in proceeds of over ...

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com

1 week from now

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com UK

1 week from now

May 15, 2024 · Evolus (NASDAQ: EOLS), Inc. CEO David Moatazedi recently completed a stock sale transaction, disposing of a total of 16,051 shares of the company's common stock, …

investing.com

$113966
OFF

Evolus CEO David Moatazedi Sells $113,966 In Stock - Investing.com

1 week from now

Dec 26, 2024 · Evolus CEO David Moatazedi sells $113,966 in stock ... recently sold 10,502 shares of the company's common stock. The shares were sold at an average price of …

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com ZA

1 week from now

May 15, 2024 · Read Evolus CEO sells over $200k in company stock By Investing.com. Evolus CEO sells over $200k in company stock. Download the App. More markets insights, more …

investing.com

34%
OFF

Evolus CEO David Moatazedi Sells $113,966 In Stock

1 week from now

Dec 26, 2024 · David Moatazedi, President and CEO of Evolus, Inc. (NASDAQ: EOLS), a company showing strong revenue growth of ~34% year-over-year and currently trading below …

investing.com

34%
OFF

Evolus CEO David Moatazedi Sells $113,966 In Stock

1 week from now

Dec 26, 2024 · David Moatazedi, President and CEO of Evolus, Inc. (NASDAQ: EOLS), a company showing strong revenue growth of ~34% year-over-year and currently trading below …

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com India

1 week from now

Evolus CEO sells over $200k in company stock

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000

1 week from now

Sep 7, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000.The sale, dated …

investing.com

$24438
OFF

Evolus Chief Medical Officer Sells Shares Worth $24,438

1 week from now

Dec 26, 2024 · NEWPORT BEACH, CA—Evolus, Inc. (NASDAQ: EOLS) Chief Medical (TASE: PMCN) Officer and Head of Research and Development, Rui Avelar, has recently sold 2,252 …

investing.com

34%
OFF

Evolus CFO Sandra Beaver Sells Shares Worth $17,211

1 week from now

Dec 26, 2024 · Sandra Beaver, Chief Financial Officer of Evolus, Inc. (NASDAQ: EOLS), a company that has shown strong revenue growth of 34% in the last twelve months, recently …

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000

1 week from now

Sep 6, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000. The sale, dated …

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000

1 week from now

Sep 7, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000.The sale, dated …

investing.com

$24438
OFF

Evolus Chief Medical Officer Sells Shares Worth $24,438

1 week from now

Dec 26, 2024 · Evolus chief medical officer sells shares worth $24,438 ... Rui Avelar, has recently sold 2,252 shares of the company's common stock. The transaction, which took place on …

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000 By …

1 week from now

Sep 6, 2024 · Evolus, Inc.'s (NASDAQ:) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000. The sale, dated Saturday, 28 …

vcptrading.com

34%
OFF

Evolus CFO Sandra Beaver Sells Shares Worth $17,211

1 week from now

Dec 26, 2024 · Sandra Beaver, Chief Financial Officer of Evolus, Inc. (NASDAQ: EOLS), a company that has shown strong revenue growth of 34% in the last twelve months, recently …

investing.com

36%
OFF

#MicroStrategy Hits 446,400 BTC Despite Stock Slump - YouTube

1 week from now

MicroStrategy now holds 446,400 BTC worth $42B, doubling down on its Bitcoin strategy even as MSTR stock drops 36% from its all-time high. Will Saylor’s bold...

youtube.com

$250
OFF

Latest Company News - Investing.com

1 week from now

3 days ago · By Investing.com • Mar 26, 2024. Rent the Runway announces 1-for-20 reverse stock split ... Ecovyst director Susan Ward sells over $250k in company stock. ... Powerschool …

investing.com

62%
OFF

Evolus Stock Soars To 52-week High, Hits $17.75 - Investing.com

1 week from now

Oct 14, 2024 · Evolus stock soars to 52-week high, hits $17.75 ... The company's stock has demonstrated a robust 107.62% price total return over the past year, aligning closely with the …

investing.com

FAQs about Evolus CEO sells over $200k in company stock - Investing.com Coupon?

What happened to Evolus stock in November?

Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November. It mounted a slight comeback to ~$14 per share, then crashed again in December, and has kept falling to its current price of $9.3 per share. What, then, is turning the market against Evolus and its business? ...

Is Evolus a profitable stock?

Full-year revenue guidance was “narrowed” to $260m - $266m — an annual uplift of 29% - 32% — and stated it would be profitable on a non-GAAP basis in Q4 2024, and in full-year 2025, and finally, that it: Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November. ...

Should you buy Evolus stock after Q3 earnings?

Unfortunately, although Evolus stock enjoyed a strong bull run between June and early November last year, with shares reaching a high of $17 per share, a market cap valuation of roughly just under $1bn, it then began to tumble in value after Evolus released a weak set of Q3 earnings. At first, the results and updates appear quite positive. ...

Should I buy Evolus?

My “Buy” recommendation was based on several factors. Firstly, the company has settled litigation with AbbVie (ABBV), who market and sell Botox, the leading product in the field, which earned $2.7bn in aesthetics markets, and $3bn as a migraine therapy, in 2023. AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. ...

Is Evolus launching a second product?

Well, between 2020 and 2023 Evolus nearly quadrupled its revenues, and it is in the process of launching a second product that could be even more lucrative. ...

Did Evolus steal trade secrets?

AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. However, the litigation was settled, with AbbVie granting Evolus a license to keep selling its product. ...